
Validea's 'Patient Investor' model, based on Warren Buffett's strategy, assigned Lam Research Corporation (LRCX) an 86% rating, highlighting strong fundamental alignment for predictable profitability and low debt. As a large-cap semiconductor growth stock, LRCX passed most key criteria, including earnings predictability, debt service, and free cash flow, but notably failed on Return on Total Capital. This assessment suggests LRCX warrants attention for investors prioritizing long-term value and stability within the semiconductor industry.
Lam Research Corporation (LRCX) scores an 86% on Validea's 'Patient Investor' model, which is based on Warren Buffett's investment philosophy, indicating a strong alignment with criteria favoring long-term, predictable profitability and low debt. As a large-cap growth stock in the semiconductor industry, LRCX successfully passed a majority of the model's fundamental tests, including key metrics such as Earnings Predictability, Debt Service, Free Cash Flow, and Share Repurchases. This suggests the company demonstrates consistent financial health and a shareholder-friendly capital allocation policy. However, the analysis also flags a notable weakness, as the company failed the test for Return on Total Capital (ROTC). While the overall assessment is positive and highlights multiple strengths consistent with a durable business, the underperformance in ROTC presents a specific point of concern regarding the firm's efficiency in generating profits from its entire capital base.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment